Paricalcitol plus chemotherapy raised partial response to 42% vs 9% in pancreatic cancer
Louis summarizes a small Dana-Farber randomized trial (Nature Cancer) of a synthetic vitamin D analog added to gemcitabine plus nab-paclitaxel in 36 patients. Tumour vitamin D receptor levels tracked with longest survival. Small and early, so not definitive.


